Citations (57)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Claudia Djambas Khayat, Genadi Iosava, Irina Romashevskaya, Oleksandra Stasyshyn, Marta Julia Lopez, Maria Teresa Pompa, Tobias Rogosch & Wilfried Seifert. (2021) Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study). Journal of Blood Medicine 12, pages 483-495.
Read now
Read now
Massimo Morfini & Emanuela Marchesini. (2020) The availability of new drugs for hemophilia treatment. Expert Review of Clinical Pharmacology 13:7, pages 721-738.
Read now
Read now
Niloofar Naderi, Fariba Ebrahimzadeh, Mohammad Jazebi, Ali Namvar, Mehrdad Hashemi & Azam Bolhassani. (2018) Polymorphisms in the TGF-β1 (rs1982037) and IL-2 (rs2069762, rs4833248) genes are not associated with inhibitor development in Iranian patients with hemophilia A. Hematology 23:10, pages 839-843.
Read now
Read now
Massimo Morfini. (2017) Simoctocog alfa for the treatment of hemophilia A. Expert Opinion on Biological Therapy 17:12, pages 1573-1580.
Read now
Read now
Articles from other publishers (53)
Zimin Sun, Yaming Xi, Wei Liu, Linhua Yang, Xuefeng Wang, Chenghao Jin, Haifei Jia & Lei Zhang. (2023) Efficacy and safety of the B‐domain‐deleted TQG202 for on‐demand treatment in moderate and severe haemophilia A patients: A multicentre, single‐arm trial. Haemophilia.
Crossref
Crossref
Nirmalkumar Choraria, Savita Rangarajan, M. Joseph John, Shashikant Apte, Pritam Gupta, Seema Pai, Rohit Chand, Shyam Parvatini, G. S. H. Ramakanth, Jeremy Rupon, Amit Chhabra, Hitesh Bhaskarrao Muley & Damien Simoneau. (2022) Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India. Indian Journal of Hematology and Blood Transfusion.
Crossref
Crossref
David W. Uster, Pratima Chowdary, Anne Riddell, Cecilia Garcia, Elsa Aradom, Molly Musarara & Sebastian G. Wicha. (2022) Dosing for Personalized Prophylaxis in Hemophilia A Highly Varies on the Underlying Population Pharmacokinetic Models. Therapeutic Drug Monitoring 44:5, pages 665-673.
Crossref
Crossref
Valentina Drago, Luisa Di Paola, Claire Lesieur, Renato Bernardini, Claudio Bucolo & Chiara Bianca Maria Platania. (2022) In-Silico Characterization of von Willebrand Factor Bound to FVIII. Applied Sciences 12:15, pages 7855.
Crossref
Crossref
Jens Müller, Wolfgang Miesbach, Florian Prüller, Thomas Siegemund, Ute Scholz & Ulrich J. Sachs. (2022) An Update on Laboratory Diagnostics in Haemophilia A and B. Hämostaseologie 42:04, pages 248-260.
Crossref
Crossref
Kelvin Kohar, Stephanie A Prayogo & Lowilius Wiyono. (2022) The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis. Cureus.
Crossref
Crossref
Doddolla Lingamaiah, Sunitha NS, Krishna Murti, Sanjiv Singh, V. Ravichandiran & Sameer Dhingra. (2022) Emicizumab: an FDA-Approved Monoclonal Antibody in the Treatment of Hemophilia A. Current Pharmacology Reports 8:2, pages 121-129.
Crossref
Crossref
Fanny Risser, Ivan Urosev, Joanan López-Morales, Yang Sun & Michael A. Nash. (2022) Engineered Molecular Therapeutics Targeting Fibrin and the Coagulation System: a Biophysical Perspective. Biophysical Reviews 14:2, pages 427-461.
Crossref
Crossref
Irving Jair Lara-Navarro & Ana Rebeca Jaloma-Cruz. (2022) Current Therapies in Hemophilia: From Plasma-Derived Factor Modalities to CRISPR/Cas Alternatives. The Tohoku Journal of Experimental Medicine 256:3, pages 197-207.
Crossref
Crossref
Paramita Gayen, Somnath Jan, Nilkanta Chowdhury, Snehasish Ghosh, Monjuri Hembram, Angshuman Bagchi & Rituparna Sinha Roy. (2021) Engineered Bio‐inspired Multifunctional Peptide‐ and Protein‐based Therapeutic Biomolecules for Better Wound Care. Chemistry – An Asian Journal 16:24, pages 4018-4036.
Crossref
Crossref
Roberto Ucero-Lozano, José Antonio López-Pina, Alba Ortiz-Pérez & Rubén Cuesta-Barriuso. (2021) Quality of life and its predictors among adult patients with haemophilic arthropathy. An observational study. BMC Musculoskeletal Disorders 22:1.
Crossref
Crossref
Ri J. Liesner, Aby Abraham, Carmen Altisent, Mark J. Belletrutti, Manuel Carcao, Manuela Carvalho, Hervé Chambost, Anthony K. C. Chan, Leonid Dubey, Jonathan Ducore, Michael Gattens, Paolo Gresele, Yves Gruel, Benoit Guillet, Victor Jimenez-Yuste, Lidija Kitanovski, Anna Klukowska, Sunil Lohade, Maria Elisa Mancuso, Johannes Oldenburg, Anna Pavlova, Berardino Pollio, Marianne Sigaud, Vladimir Vdovin, Kateryna Vilchevska, John K. M. Wu, Martina Jansen, Larisa Belyanskaya, Olaf Walter, Sigurd Knaub & Ellis J. Neufeld. (2021) Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study. Thrombosis and Haemostasis 121:11, pages 1400-1408.
Crossref
Crossref
Tahereh Zadeh Mehrizi & Kamran Mousavi Hosseini. (2021) An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010–2020 review. Nanoscale Advances 3:13, pages 3730-3745.
Crossref
Crossref
Christophe Schmitt, Joanne I. Adamkewicz, Jin Xu, Claire Petry, Olivier Catalani, Guy Young, Claude Negrier, Michael U. Callaghan & Gallia G. Levy. (2020) Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thrombosis and Haemostasis 121:03, pages 351-360.
Crossref
Crossref
Wolfgang Miesbach & Erik Berntorp. (2021) Translating the success of prophylaxis in haemophilia to von Willebrand disease. Thrombosis Research 199, pages 67-74.
Crossref
Crossref
K John Pasi. (2021)
Efficacy of Nuwiq
®
(Simoctocog Alfa) in Patients with Hemophilia A Who Changed and Adhered to a Pharmacokinetic-Guided Prophylaxis Regimen in the NuPreviq Study
. Clinical Medicine Insights: Blood Disorders 14, pages 263485352199151.
Crossref
Crossref
Carmen Escuriola Ettingshausen & Robert F. SidonioJr.Jr.. (2021) Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemophilia A (MOTIVATE). Therapeutic Advances in Hematology 12, pages 204062072110324.
Crossref
Crossref
Yongqiang Zhao, Yu Hu, Jie Jin, Xielan Zhao, Xuefeng Wang, Runhui Wu, Depei Wu, Renchi Yang, Feng’e Yang, Qun Hu, Juan Wang, Hai Fang & Werner Engl. (2021) Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A. Clinical and Applied Thrombosis/Hemostasis 27, pages 107602962198981.
Crossref
Crossref
Christine Keipert, Ursula Drechsel-Bäuerle, Doris Oberle, Mirco Müller-Olling & Anneliese Hilger. (2020) Epidemiological Challenges in Rare Bleeding Disorders: FVIII Inhibitor Incidence in Haemophilia A Patients—A Known Issue of Unknown Origin. International Journal of Environmental Research and Public Health 18:1, pages 225.
Crossref
Crossref
Jun Su, Nanxin Li, Namita Joshi, Xinyi Ng, Marc Botteman, Rachel Shah, Nisha Jain, Nicole Lyn & Ronald Preblick. (2020) Patient and caregiver preferences for haemophilia A treatments: A discrete choice experiment. Haemophilia 26:6.
Crossref
Crossref
Songkai YanGéraldine S. MaroVidhi DesaiMindy L. Simpson. (2020) A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients. Journal of Managed Care & Specialty Pharmacy 26:10, pages 1258-1265.
Crossref
Crossref
Guy-Alain Junter & Laurent Lebrun. (2020) Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance. Journal of Pharmaceutical Analysis 10:4, pages 291-312.
Crossref
Crossref
Pratima Chowdary, Eric S. Mullins, Barbara A. Konkle, Catherine McGuinn, Young Shil Park, Oleksandra Stasyshyn, Bülent Zulfikar, Werner Engl & Srilatha Tangada. (2020) Long‐term safety and efficacy results from the phase 3b, open‐label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia 26:4.
Crossref
Crossref
Chun-Yu Chen, Dominic M. Tran, Alex Cavedon, Xiaohe Cai, Raj Rajendran, Meghan J. Lyle, Paolo G.V. Martini & Carol H. Miao. (2020) Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles. Molecular Therapy - Nucleic Acids 20, pages 534-544.
Crossref
Crossref
Shadan Lalezari, Michaël Acquadro, Elodie de Bock, Jérémy Lambert & Mindy L. Simpson. (2020) Comparing Physician and Patient Perspectives on Prophylactic Treatment with BAY 94-9027 for Severe Haemophilia A: A Post Hoc Analysis. Advances in Therapy 37:6, pages 2763-2776.
Crossref
Crossref
Quentin Allard, Zoubir Djerada, Claire Pouplard, Yohann Repessé, Dominique Desprez, Hubert Galinat, Birgit Frotscher, Claire Berger, Annie Harroche, Anne Ryman, Claire Flaujac, Pierre Chamouni, Benoît Guillet, Fabienne Volot, Jean Szymezak, Philippe Nguyen & Yoann Cazaubon. (2020) Real Life Population Pharmacokinetics Modelling of Eight Factors VIII in Patients with Severe Haemophilia A: Is It Always Relevant to Switch to an Extended Half-Life?. Pharmaceutics 12:4, pages 380.
Crossref
Crossref
Mindy L. SimpsonVidhi DesaiGéraldine S. MaroSongkai Yan. (2020) Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products. Journal of Managed Care & Specialty Pharmacy 26:4, pages 504-512.
Crossref
Crossref
Erna C. van Balen, Marjolein L. Wesselo, Bridget L. Baker, Marjan J. Westerman, Michiel Coppens, Cees Smit, Mariëtte H. E. Driessens, Frank W. G. Leebeek, Johanna G. van der Bom & Samantha C. Gouw. (2019) Patient Perspectives on Novel Treatments in Haemophilia: A Qualitative Study. The Patient - Patient-Centered Outcomes Research 13:2, pages 201-210.
Crossref
Crossref
Debra Pollard, Kate Khair & Mike Holland. (2020) Experience of switching to NovoEight: views of people with haemophilia. The Journal of Haemophilia Practice 7:1, pages 70-77.
Crossref
Crossref
Mariana Sayago & Cláudio Lorenzo. (2020) O acesso global e nacional ao tratamento da hemofilia: reflexões da bioética crítica sobre exclusão em saúde. Interface - Comunicação, Saúde, Educação 24.
Crossref
Crossref
Cedric Hermans & Gerry Dolan. (2020) Pharmacokinetics in routine haemophilia clinical practice: rationale and modalities—a practical review. Therapeutic Advances in Hematology 11, pages 204062072096688.
Crossref
Crossref
Juliana Coronel, Christoph Heinrich, Sandra Klausing, Thomas Noll, Alvio Figueredo‐Cardero & Leda R. Castilho. (2019) Perfusion process combining low temperature and valeric acid for enhanced recombinant factor VIII production. Biotechnology Progress 36:1.
Crossref
Crossref
Amanda D. Sankar, Angela C. Weyand & Steven W. Pipe. (2019) The evolution of recombinant factor replacement for hemophilia. Transfusion and Apheresis Science 58:5, pages 596-600.
Crossref
Crossref
Chur Woo You, Hee Jo Baek, Sang Kyu Park, Young Shil Park, Ho-Jin Shin, Werner Engl & Srilatha Tangada. (2019) Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients. BLOOD RESEARCH 54:3, pages 198-203.
Crossref
Crossref
Stefan Tiefenbacher, Manuela Albisetti, Peter Baker, Guenther Kappert, Steve Kitchen, Johanna A. Kremer Hovinga, Claire Pouplard, Ute Scholz, Catherine Ternisien, Carin Borgvall, Tiago Vicente, Larisa Belyanskaya, Olaf Walter & Johannes Oldenburg. (2019)
Estimation of Nuwiq
®
(simoctocog alfa) activity using one‐stage and chromogenic assays—Results from an international comparative field study
. Haemophilia 25:4, pages 708-717.
Crossref
Crossref
Julia Paik & Emma D. Deeks. (2019) Damoctocog Alfa Pegol: A Review in Haemophilia A. Drugs 79:10, pages 1147-1156.
Crossref
Crossref
Bethany Samuelson Bannow, Michael Recht, Claude Négrier, Cédric Hermans, Erik Berntorp, Hermann Eichler, Maria Elisa Mancuso, Robert Klamroth, Jamie O'Hara, Elena Santagostino, Tadashi Matsushita & Craig Kessler. (2019) Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Reviews 35, pages 43-50.
Crossref
Crossref
Pankaj Abrol. 2019. Hemophilia - Recent Advances. Hemophilia - Recent Advances.
Babbal, Adivitiya, Shilpa Mohanty & Yogender Pal Khasa. 2019. High Value Fermentation Products. High Value Fermentation Products
225
263
.
Elena Santagostino, Savita Rangarajan, Johannes Oldenburg, Roser Peiró‐Jordan & Víctor Jiménez‐Yuste. (2019) Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate. Haemophilia 25:2.
Crossref
Crossref
Cristina Scavone, Gabriella di Mauro, Annamaria Mascolo, Liberato Berrino, Francesco Rossi & Annalisa Capuano. (2019) The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs. Frontiers in Pharmacology 10.
Crossref
Crossref
Toshko Lissitchkov, Anna Klukowska, John Pasi, Craig M. Kessler, Robert Klamroth, Raina J. Liesner, Larisa Belyanskaya, Olaf Walter, Sigurd Knaub, Johann Bichler, Martina Jansen & Johannes Oldenburg. (2019) Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program. Therapeutic Advances in Hematology 10, pages 204062071985847.
Crossref
Crossref
Jean-Charles Ryff & Sidney Pestka. 2019. Pharmaceutical Biotechnology. Pharmaceutical Biotechnology
619
643
.
Ana Catarina Silva, Cládia Pina Costa, Hugo Almeida, João Nuno Moreira & José Manuel Sousa Lobo. 2020. Current Applications of Pharmaceutical Biotechnology. Current Applications of Pharmaceutical Biotechnology
115
153
.
Clémence Merlen, Nichan Zourikian, Arnaud Bonnefoy, Evemie Dubé, Catherine Thibeault, Jean St-Louis & Georges-Etienne Rivard. (2018) Effect of ABO blood group on haemostatic parameters in severe haemophilia A patients performing acute moderate-intensity exercise. Blood Coagulation & Fibrinolysis 29:7, pages 626-635.
Crossref
Crossref
S.T. Mannully, Ramya L.N.K.K. Pulicherla. (2018) Perspectives on progressive strategies and recent trends in the production of recombinant human factor VIII. International Journal of Biological Macromolecules 119, pages 496-504.
Crossref
Crossref
C. Bartholdy, S. L. Reedtz-Runge, J. Wang, L. Hjerrild Zeuthen, A. Gruhler, C. N. Gudme & K. Lamberth. (2018) In silico and in vitro immunogenicity assessment of B-domain-modified recombinant factor VIII molecules. Haemophilia 24:5, pages e354-e362.
Crossref
Crossref
A. Klukowska, T. Szczepański, V. Vdovin, S. Knaub, J. Bichler, M. Jansen, I. Dzhunova & R. J. Liesner. (2018)
Long-term tolerability, immunogenicity and efficacy of Nuwiq
®
(human-cl rhFVIII) in children with severe haemophilia A
. Haemophilia 24:4, pages 595-603.
Crossref
Crossref
Vijaya S. Pilli. 2018. Hematology - Latest Research and Clinical Advances. Hematology - Latest Research and Clinical Advances.
Gary M. Woods, Michael W. Dunn & Amy L. Dunn. (2018) Emergencies in Hemophilia. Clinical Pediatric Emergency Medicine 19:2, pages 110-121.
Crossref
Crossref
M. Carcao, A. Shapiro, J. M. Staber, N. Hwang, C. Druzgal, K. Lieuw, M. Belletrutti, C. D. Thornburg, S. P. Ahuja, J. Morales-Arias, J. Dumont, G. Miyasato, E. Tsao, N. Jain & S. W. Pipe. (2018) Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis. Haemophilia 24:2, pages 245-252.
Crossref
Crossref
Vincent P. Mauro. (2018) Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations. BioDrugs 32:1, pages 69-81.
Crossref
Crossref
N. Zozulya, C. M. Kessler, A. Klukowska, M. von Depka, K. Hampton, C. R. M. Hay, M. Jansen, J. Bichler, S. Knaub & S. Rangarajan. (2018)
Efficacy and safety of Nuwiq
®
(human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures
. Haemophilia 24:1, pages 70-76.
Crossref
Crossref